Adenosine: Pharmacology and Half-Life
Adenosine has an exceptionally short plasma half-life of less than 10 seconds, which is the key pharmacological property that makes it both highly effective and remarkably safe for acute termination of supraventricular tachycardia. 1
What is Adenosine?
Adenosine is an endogenous nucleoside (6-amino-9-beta-D-ribofuranosyl-9-H-purine) with the molecular formula C₁₀H₁₃N₅O₄ and molecular weight of 267.24. 1 It functions as a naturally occurring compound in the body that acts on purine receptors (A1 and A2 adenosine receptors) on cell surfaces. 1
Mechanism of Action
Cardiac effects: Adenosine produces direct negative chronotropic, dromotropic, and inotropic effects on the heart through A1-receptor agonism, causing transient AV nodal block. 1
Vascular effects: It causes peripheral vasodilation through A2-receptor activation, resulting in mild to moderate reductions in blood pressure with reflex tachycardia. 1
Clinical utility: By blocking the anterograde AV nodal limb of reentrant circuits, adenosine terminates AVNRT and AVRT with success rates of 78-96%. 2
Pharmacokinetics and Half-Life
Plasma Half-Life
The half-life of adenosine in whole blood is extraordinarily brief at 0.6 to 10 seconds, with most studies converging on approximately 1-2 seconds at physiological temperature. 1, 3, 4, 5
Metabolism and Clearance
Primary clearance mechanism: Adenosine is rapidly cleared from plasma by cellular uptake, primarily by erythrocytes and vascular endothelial cells, via a specific transmembrane nucleoside carrier system. 1, 4
Intracellular metabolism: Once inside cells, adenosine undergoes two main metabolic pathways: 1
- Phosphorylation to adenosine monophosphate by adenosine kinase (primary pathway)
- Deamination to inosine by adenosine deaminase (secondary pathway when phosphorylation is saturated)
Distribution: The drug distributes rapidly from circulation via cellular uptake rather than through traditional hepatic or renal metabolism. 1
Clinical Implications of Short Half-Life
Safety Profile
Transient adverse effects: Common side effects including chest discomfort, dyspnea, flushing, and headache typically resolve within 1 minute of onset due to the ultra-short half-life. 2, 3, 5, 6
Serious adverse effects are rare: The brief duration of action means that even significant adverse reactions (hypotension, arrhythmias, AV block) are self-limiting and resolve quickly when infusion is discontinued. 2, 1
Dosing Strategy
Rapid titration possible: The short half-life allows for rapid upward dosage titration if initial doses are ineffective, without risk of drug accumulation. 5
Standard dosing: Initial 6 mg rapid IV bolus, followed by up to two 12 mg boluses at 1-2 minute intervals if needed. 2, 3
Administration technique critical: Must be given as rapid bolus via proximal IV followed by saline flush to ensure drug reaches the heart before being metabolized. 2
Special Populations
Renal impairment: No dose adjustment needed, as adenosine does not require renal function for activation or inactivation. 1
Hepatic impairment: No dose adjustment needed, as adenosine does not require hepatic function for activation or inactivation. 1
Important Clinical Caveats
Methylxanthine antagonism: Caffeine, aminophylline, and theophylline are competitive adenosine receptor antagonists that can block adenosine's effects or be used to reverse persistent adverse reactions (50-125 mg theophylline IV). 1
Dipyridamole potentiation: This nucleoside transport inhibitor blocks adenosine uptake and can significantly prolong and intensify adenosine's effects. 4
Measurement challenges: Due to the extremely short half-life, accurate measurement of plasma adenosine requires specialized collection techniques with immediate metabolic inhibition. 7